Immuron (IMRN) Cash from Financing Activities (2016 - 2024)
Immuron's quarterly Cash from Financing Activities came in at -$27401.4 in Q4 2024, down 81.67% year-on-year from -$149453.5 in Q1 2024, and down 81.67% quarter-over-quarter from -$15083.4 in Q4 2023.
Immuron has reported Cash from Financing Activities for 8 years, with the latest figure at -$27401.4 in Q4 2024.
- For the quarter ending Q4 2024, Cash from Financing Activities fell 81.67% year-over-year to -$27401.4; the trailing twelve-month figure through Dec 2024 stood at -$61958.9 (down 100.23% YoY), and the FY2025 full-year result was $199747.0, up 23994.93% from the prior year.
- Cash from Financing Activities for Q4 2024 stood at -$27401.4, down from -$15083.4 in the prior quarter.
- The five-year high for Cash from Financing Activities was $26.6 million in Q4 2020, with the low at -$27401.4 in Q4 2024.
- Average Cash from Financing Activities over 5 years is $5.3 million, with a median of -$15083.4 recorded in 2023.
- Year-over-year, Cash from Financing Activities surged 2007.11% in 2020 and slumped 1163.58% in 2022.
- Tracing IMRN's Cash from Financing Activities over 5 years: stood at $26.6 million in 2020, then sank by 99.99% to $2021.0 in 2021, then tumbled by 1163.58% to -$21495.0 in 2022, then rose by 29.83% to -$15083.4 in 2023, then sank by 81.67% to -$27401.4 in 2024.
- The last three Cash from Financing Activities figures came in at -$27401.4 (Q4 2024), -$15083.4 (Q4 2023), and -$21495.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2021 | 2,021.00 |
| Dec 31, 2021 | 2,021.00 |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2016 | 2.29 Mn |
| Dec 31, 2016 | 2.29 Mn |